For those following intermittent fasting protocols, AOD 9604 integrates seamlessly
however, given the cross-sectional design and modest sample size, this interpretation remains tentative
Clinical practitioners often pair this method with PRP or exosome therapy for compounded results
The prior authorization requirements when diabetes is present If you have type 2 diabetes and want MassHealth to cover a GLP-1 medication (Ozempic, not Wegovy), the prior authorization pathway requires: Clinical criteria: Documented type 2 diabetes diagnosis (ICD-10 code E11.x) BMI of 27 or higher At least one obesity-related comorbidity: hypertension, dyslipidemia, cardiovascular disease, or sleep apnea HbA1c of 7.0% or higher despite current therapy Trial and inadequate response to metformin for at least 90 days (documented by prescription fill history or provider attestation) Trial and inadequate response to at least one additional oral diabetes medication (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor) for at least 90 days Documentation requirements: Current HbA1c lab result (within 90 days) Current weight and BMI List of prior diabetes medications with dates and reasons for discontinuation or inadequacy Treatment plan including diet and exercise counseling The prior authorization is reviewed by MassHealth's pharmacy benefit manager (currently Gainwell Technologies as of 2026)
Boost with Vitamin C : Add oranges or strawberries to your diet to shield GlutathioneVitamin C tackles free radicals to help Glutathione stay strong and effective
